(Q38093134)

28 August 2017

title

Chronic hepatitis B in children and adolescents: epidemiology and management (English)

1 reference

28 August 2017

1 reference

1 reference

1 reference

Mona Abdel-Hady

1

1 reference

28 August 2017

Deirdre Kelly

series ordinal

2

1 reference

28 August 2017

publication date

1 August 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

15

1 reference

28 August 2017

issue

4

1 reference

28 August 2017

page(s)

311-317

1 reference

https://scigraph.springernature.com/pub.10.1007/s40272-013-0010-z

28 August 2017

exact match

0 references

cites work

A mathematical model to estimate global hepatitis B disease burden and vaccination impact.

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Therapeutic implications of hepatitis B virus genotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Hepatitis B genotypes and response to antiviral therapy: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

International trends and patterns of primary liver cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Hepatitis B virus screening for internationally adopted children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

High levels of hepatitis B virus DNA in body fluids from chronic carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Chronic hepatitis B in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Effect of human milk and epidermal growth factor on growth of human intestinal Caco-2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Risk factors and mechanism of transplacental transmission of hepatitis B virus: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Breastfeeding and chronic HBV infection: clinical and social implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Should chronic hepatitis B mothers breastfeed? a meta analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Duration of hepatitis B immunity in low risk children receiving hepatitis B vaccinations from birth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Viremia profiles in children with chronic hepatitis B virus infection and spontaneous e antigen seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Immune tolerance split between hepatitis B virus precore and core proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Molecular characteristics and stages of chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Chronic hepatitis B in children after e antigen seroclearance: final report of a 29-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Natural history and clinical management of chronic hepatitis B virus infection in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Hepatitis B virus resistance to nucleos(t)ide analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Management of chronic hepatitis B in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Clinical trial of lamivudine in children with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Drug safety evaluation of adefovir in HBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Interferon-alpha treatment of chronic hepatitis B in childhood: a consensus advice based on experience in European children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Long term effect of alpha interferon in children with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Lamivudine for patients with chronic hepatitis B and advanced liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Side effects of long-term oral antiviral therapy for hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Treatment of recurrent hepatitis B infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40272-013-0010-Z

Long-term outcome in children with chronic hepatitis B: a 24-year observation period

21 January 2018

1 reference

12 December 2020

Comparison of two different regimens of combined interferon-alpha2a and lamivudine therapy in children with chronic hepatitis B infection

1 reference

12 December 2020

Long-term follow-up of hepatitis B carrier children treated with interferon and prednisolone

1 reference

12 December 2020

The natural history of chronic hepatitis B virus infection

1 reference

12 December 2020

Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B

1 reference

12 December 2020

Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F

1 reference

12 December 2020

Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B

1 reference

12 December 2020

Viral mutants and fulminant hepatitis. A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis

1 reference

12 December 2020

Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B

1 reference

12 December 2020

10.1007/S40272-013-0010-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1021263662

0 references

1 reference